Almudena García-Ortiz

Almudena García-Ortiz

Auto-generated profile, based on publicly available information

Almudena García-Ortiz

H12O-CNIO Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Advanced Therapies Manufacturing Unit, Hospital Universitario 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AGAlmudena García-Ortiz
Almudena García-Ortiz
YRYaiza Rodríguez-García
Yaiza Rodríguez-García
JEJessica Encinas
Jessica Encinas
EMElena Maroto Martín
Elena Maroto Martín
ECEva Castellano
Eva Castellano
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
Multiple myeloma (MM) is a hematologic cancer characterized by clonal proliferation of plasma cells in the bone marrow (BM). The progression, from the early stages of the disease as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to MM and occasionally extramedullary disease, is drastically affected by the tumor microenvironment (TME). Soluble factors and direct cell–cell interactions regulate MM plasma cell trafficking and homing to the BM niche. Mesenchymal stromal cells, osteoclasts, osteoblasts, myeloid and lymphoid cells present in the BM create a unique milieu that favors MM plasma cell immune evasion and promotes disease progression. Moreover, TME is implicated in malignant cell protection against anti-tumor therapy. This review describes the main cellular and non-cellular components located in the BM, which condition the immunosuppressive environment and lead the MM establishment and progression.

14 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
LDLaura Díez-Alonso
Laura Díez-Alonso
AFAïda Falgas
Aïda Falgas
JAJavier Arroyo-Ródenas
Javier Arroyo-Ródenas
PRPaola A. Romencín
Paola A. Romencín
AMAlba Martínez
Alba Martínez
LALuis Alvarez-Vallina
Luis Alvarez-Vallina
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric antigen receptors (CARs) and systemically injected bispecific T cell engagers (TCEs), has shown remarkable clinical activity, and several products have received market approval. However, despite promising results, most patients eventually become refractory and relapse, highlighting the need for alternative strategies. Engineered T cells secreting TCE antibodies (STAb) represent a promising strategy that combines the advantages of adoptive cell therapies and bispecific antibodies. Here, we undertook a comprehensive preclinical study comparing the therapeutic potential of T cells either expressing second-generation anti-BCMA CARs (CAR-T) or secreting BCMAxCD3 TCEs (STAb-T) in a T cell–limiting experimental setting mimicking the conditions found in patients with relapsed/refractory multiple myeloma. STAb-T cells recruited T cell activity at extremely low effector-to-target ratios and were resistant to inhibition mediated by soluble BCMA released from the cell surface, resulting in enhanced cytotoxic responses and prevention of immune escape of multiple myeloma cells in vitro. These advantages led to robust expansion and persistence of STAb-T cells in vivo, generating long-lived memory BCMA-specific responses that could control multiple myeloma progression in xenograft models, outperforming traditional CAR-T cells. These promising preclinical results encourage clinical testing of the BCMA-STAb-T cell approach in relapsed/refractory multiple myeloma.

1 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Alejandra ortiz-ruizAlejandra ortiz-ruiz
Alejandra ortiz-ruiz
YRYanira Ruiz-Heredia
Yanira Ruiz-Heredia
MMMaría Luz Morales
María Luz Morales
PAPedro Aguilar-Garrido
Pedro Aguilar-Garrido
AGAlmudena García-Ortiz
Almudena García-Ortiz
MGMiguel Gallardo
Miguel Gallardo
Mitochondria are involved in the development and acquisition of a malignant phenotype in hematological cancers. Recently, their role in the pathogenesis of multiple myeloma (MM) has been suggested to be therapeutically explored. MYC is a master regulator of b-cell malignancies such as multiple myeloma, and its activation is known to deregulate mitochondrial function. We investigated the impact of mitochondrial activity on the distinct entities of the disease and tested the efficacy of the mitochondrial inhibitor, tigecycline, to overcome MM proliferation. COXII expression, COX activity, mitochondrial mass, and mitochondrial membrane potential demonstrated a progressive increase of mitochondrial features as the disease progresses. In vitro and in vivo therapeutic targeting using the mitochondrial inhibitor tigecycline showed promising efficacy and cytotoxicity in monotherapy and combination with the MM frontline treatment bortezomib. Overall, our findings demonstrate how mitochondrial activity emerges in MM transformation and disease progression and the efficacy of therapies targeting these novel vulnerabilities.

20 November 2025 in Cytotherapy
Verified
Journal Article
Open access
LCLaura Córdoba-Espejo
Laura Córdoba-Espejo
LSLaura Sánchez-Vega
Laura Sánchez-Vega
AGAlmudena García-Ortiz
Almudena García-Ortiz
ECEva Castellano
Eva Castellano
RORaquel Oliva
Raquel Oliva
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
Chimeric Antigen Receptor (CAR)-T cell therapy has shown promising results in hematological malignancies but faces limitations such as the need for autologous products or additional modifications of allogeneic T cell sources to prevent graft-versus-host disease (GvHD). In acute myeloid leukemia (AML), its application is particularly challenging due to antigen overlap between malignant cells and healthy hematopoietic stem cells, leading to severe and often fatal toxicities due to on-target, off-tumor effect. Natural killer (NK) cells offer a promising alternative for CAR therapy, as they are well tolerated and exert antitumor activity beyond CAR-mediated mechanisms. Peripheral blood (PB) is an accessible NK cell source with a relatively high proportion of mature NK cells; however, generating clinically relevant numbers of highly transduced PB-derived CAR-NK cells in closed systems remains challenging, and production protocols need optimization. Here, we evaluated different manufacturing strategies to generate NKG2D CAR-NK cells from PB in the CliniMACS Prodigy closed platform. We established an optimized protocol that achieved enhanced transduction efficiency, yielding high numbers of CAR+ cells. The final product met good manufacturing practice (GMP)-aligned safety and sterility requirements, displayed superior in vitro cytotoxicity against AML cell lines compared to the same product manufactured in the preclinical setting, and delayed tumor progression in an AML xenografted mouse model without cytokine support. This standardized, GMP-compliant protocol provides a robust platform for producing PB-derived CAR-NK cell therapies in a closed platform, advancing their clinical translation.